|
gptkbp:instance_of
|
gptkb:pharmaceuticals
|
|
gptkbp:clinical_trial
|
gptkb:Europe
gptkb:Canada
gptkb:United_States
Phase 2
Syndax Pharmaceuticals
|
|
gptkbp:collaboration
|
gptkb:University_of_California
|
|
gptkbp:collaborations
|
academic institutions
biotech companies
|
|
gptkbp:data_monitoring
|
independent board
|
|
gptkbp:developed_by
|
Syndax Pharmaceuticals
|
|
gptkbp:development
|
3-5 years
|
|
gptkbp:discovery_year
|
gptkb:2020
|
|
gptkbp:dosage_form
|
100 mg
|
|
gptkbp:efficacy_study
|
ongoing
|
|
gptkbp:formulation
|
gptkb:tablet
oral tablet
|
|
gptkbp:funding
|
government grants
private investment
|
|
https://www.w3.org/2000/01/rdf-schema#label
|
SYN-001
|
|
gptkbp:indication
|
gptkb:Canis_lupus
gptkb:rheumatoid_arthritis
gptkb:multiple_sclerosis
|
|
gptkbp:intended_use
|
treatment of autoimmune diseases
|
|
gptkbp:invention
|
patented
|
|
gptkbp:investigator_initiated_trial
|
yes
|
|
gptkbp:investment
|
high
|
|
gptkbp:is_effective_against
|
under investigation
|
|
gptkbp:market_position
|
not yet approved
|
|
gptkbp:mechanism_of_action
|
inhibits immune response
|
|
gptkbp:patient_population
|
autoimmune patients
|
|
gptkbp:project
|
clinical development
|
|
gptkbp:publication
|
peer-reviewed journals
scientific conferences
clinical trial results
|
|
gptkbp:recruitment
|
active
|
|
gptkbp:regulatory_body
|
gptkb:FDA
gptkb:EMA
|
|
gptkbp:regulatory_compliance
|
under review
|
|
gptkbp:research_areas
|
immunology
|
|
gptkbp:research_focus
|
autoimmunity
|
|
gptkbp:research_status
|
ongoing
|
|
gptkbp:route_of_administration
|
oral
|
|
gptkbp:safety_features
|
under evaluation
|
|
gptkbp:safety_measures
|
ongoing
|
|
gptkbp:service_frequency
|
once daily
|
|
gptkbp:side_effect
|
fatigue
headache
nausea
allergic reactions
liver toxicity
kidney issues
|
|
gptkbp:structure
|
C12 H15 N3 O3 S
|
|
gptkbp:target_audience
|
gptkb:children
adults
|
|
gptkbp:targets
|
gptkb:T_cells
|
|
gptkbp:type
|
gptkb:Atom
|
|
gptkbp:used_for
|
autoimmune diseases
|